Industry News
Biotechnology Industry News

Shionogi has struck a deal to take…
Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnimed $100 million upfront for its partner’s half of the business.
Innovent Biologics’ eye disease…
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for Chinese approval of a molecule that could reduce maintenance dose frequency.
Gilead is paying $1.68 billion for…
Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
The voluntary pause comes less…
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
Despite signing a deal potentially…
Despite signing a deal potentially worth $2.1 billion, Vivtex Therapeutics CEO Thomas von Erlach, Ph.D., refuses to rest on his laurels.
Looking to devise new drug targets…
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering's Quotient Therapeutics $20 million upfront for access to the biotech’s somatic genomics platform.
Apogee Therapeutics has published…
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double their peak sales forecast to $5.2 billion.
Sanofi has returned to T-cell…
Sanofi has returned to T-cell engager territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali Therapeutics.
Artificial intelligence has long…
Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of computing is opening up at cutting-edge labs around the globe—and Big Pharmas are getting in on
Pfizer and Valneva have blamed…
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the companies still plan to file the vaccine with regulators.
When Ron Cohen, M.D., CEO of Oryon…
When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. The former internist-turned-biotech CEO knew a thing or two about
Genentech is halting development…
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two still-ongoing obesity trials.
Novartis has struck a deal to buy…
Novartis has struck a deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion upfront, securing an asset that could defend its breast cancer franchise from challengers including Eli Lilly.
Gilead has handed back a next-gen…
Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.
Renowned cardiologist Eric Topol,…
Renowned cardiologist Eric Topol, M.D., is setting sail with Flagship Pioneering as an academic advisor for the firm’s Preemptive Health and Medicine Initiative. Topol is director of the Scripps Research Translational Institute, which he founded
Genentech has elected to stop a…
Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint.
About a month after Pfizer CEO…
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, the company has trimmed another branch. Pfizer has scrapped a phase 1 antibody-drug conjugate that
Phage-focused BiomX is undergoing…
Phage-focused BiomX is undergoing a “strategic and financial reset” in efforts to improve the biotech’s financial position, mapping out a possible shift from therapeutics to the defense sector.
Fauna Bio, which signed an…
Fauna Bio, which signed an obesity-focused partnership with Lilly back in 2023, has now unveiled the target that it will be focusing on.
More than 100 marchers took to…
More than 100 marchers took to Capitol Hill on Wednesday after carrying a coffin to the FDA in a symbolic protest highlighting lives they say could be lost to regulatory delays affecting a group of

